FDA Approves Xalkori for Rare Genetic Form of Lung Cancer

Share this content:
FDA Approves Xalkori for Rare Genetic Form of Lung Cancer
FDA Approves Xalkori for Rare Genetic Form of Lung Cancer

FRIDAY, March 11, 2016 (HealthDay News) -- Xalkori (crizotinib) has been approved by the U.S. Food and Drug Administration to treat advanced non-small-cell lung cancer (NSCLC) with tumors that have a rare ROS1 gene mutation.

The drug was approved in 2011 to treat advanced NSCLC that was related to an abnormal ALK gene, the agency said Friday in a news release.

Clinical studies of 50 people with ROS1-positive NSCLC found that about two-thirds (66 percent) of participants treated with Xalkori had complete or partial shrinkage of tumors that lasted for a median of 18.3 months, the agency said.

The drug's most common side effects include nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, loss of appetite, and upper respiratory infection. More serious adverse reactions could include liver problems, lung inflammation, abnormal heartbeat, and loss of vision.

Xalkori is marketed by New York City-based Pfizer.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

MiniMed 670G hybrid closed loop system automatically monitors glucose, delivers insulin

More Evidence HPV Vaccine Protects Against Cervical Cancer

More Evidence HPV Vaccine Protects Against Cervical Cancer

Protection appears to occur even when only one or two of the recommended doses are given

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Study of millions of health records suggests an association

is free, fast, and customized just for you!

Already a member?

Sign In Now »